DelveInsight’s ‘Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Cystic Fibrosis, historical and forecasted epidemiology as well as the Cystic Fibrosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Cystic Fibrosis Overview
Cystic fibrosis is an autosomal recessive condition known as brought on by mutations in the CF transmembrane conductance regulator gene. F508del is the most prevalent variation reported globally, but there are over 2,000 others, although not all of these are disease-causing.
Cystic Fibrosis is usually diagnosed in childhood, however, adults with no symptoms (or mild symptoms) during their youth can still be found to have the disease. The signs and symptoms of Cystic Fibrosis generally begin to occur around 6-8 months after birth, though this can differ significantly from person to person. Symptoms tend to differ depending on age and can affect various areas of the body.
Cystic Fibrosis Epidemiology Insights
In 2021, the diagnosed prevalent population of CF in 7MM was 65,519. These cases are anticipated to rise during the forecasted period (2022-2032).
The estimates show that in 2021, the diagnosed prevalence of CF in the United States was 49% of all the cases in the 7MM.
Among the five major European countries, the United Kingdom had the highest diagnosed prevalent population of CF with 10,922 cases in 2021, followed by France (7,418), Germany (6,668), and Italy (5,844). While the least number of cases were observed in Spain (2,520) in the same year. All these cases are estimated to show positive growth and rise during the study period (2019-2032).
Click here to learn more about the Cystic Fibrosis Market Landscape
The Report Covers the Cystic Fibrosis Epidemiology Segmented by:
Cystic Fibrosis-diagnosed cases
Total Cystic Fibrosis incident cases
Total Cystic Fibrosis prevalent cases
Cystic Fibrosis treatment cases
Cystic Fibrosis Market Outlook
Cystic fibrosis is an autosomal recessive genetic disorder that causes damage to the lungs and the digestive system with the highest prevalence in Europe, and North America. This disease is caused by a genetic mutation in the cystic fibrosis transmembrane conductance regulator gene. The CFTR protein is a chloride-conducting trans-membrane conductance regulator belonging to the ABC transporter class which helps in the transportation of chloride ions which helps to maintain the electrochemical gradient as well as osmotic and fluid balance in the passageways. People with cystic fibrosis have difficulty breathing and suffer from bronchospasms. Hence bronchodilators are administered to them to relax the smooth muscles of airways and aid in respiration. Albuterol which is marketed as Ventolin, is the most commonly used broncho-dilating agent that provides selective agonistic action on beta2-adrenoceptors.
Key Companies Working in the Cystic Fibrosis Market
Verona Pharmaceuticals
Eloxx Pharmaceuticals, Inc.
Vertex Pharmaceuticals
Santhera Pharmaceuticals
And many others
Cystic Fibrosis Therapies Covered and Analyzed in the Report
Ensifentrine
ELX-02
Lonodelestat
Learn more about the Key Companies and Emerging Therapies in the Cystic Fibrosis Market
Table of Contents
Key Insights
Cystic Fibrosis Introduction
Executive Summary of Cystic Fibrosis
Disease Background and Overview
Epidemiology and patient population
Cystic Fibrosis Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Cystic Fibrosis Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
